background:  multiple  sclerosis  (ms) patients permanently confronted  with serious challenges from treatment regimen. developing  a new  questionnaire in ms management, through  evaluation  of patients’ perspectives   and  knowledge   regarding   treatment  will help  to  identify the  sources  of tension, and  to  build  a therapeutic   alliance.   we   purposed   to   describe    ms patient...

Interferon-beta is one of the most widely prescribed disease-modifying therapies for multiple sclerosis patients. However, this treatment only partially effective, and a significant proportion patients do not respond to drug. This paper proposes an alternative fuzzy logic system, based on opinion neurology expert, classify relapsing–remitting as high, medium, or low responders interferon-beta. ...

BACKGROUND Interferon beta is 1 of 2 first-line treatments for relapsing-remitting multiple sclerosis (MS). However, not all patients respond to interferon beta therapy, and to date there is a lack of surrogate markers that reliably correlate with responsiveness to interferon beta therapy in MS. OBJECTIVE To identify allelic variants that influence response to interferon beta therapy in patie...

A unique sequence in the mouse genome which cross-hybridized to a cloned human interferon-beta 1 gene was detected by DNA blot analysis. Taking advantage of this, a cDNA library prepared from partially purified mRNA for mouse interferon-beta was screened using human interferon-beta 1 DNA as a probe. One of the positive clones, pM beta-3, contained a 680-base pair cDNA insert, whose base sequenc...

Background: High dose Interferon Beta and Fingolimod are efficient in Multiple Sclerosis. Objectives: Comparison the efficacy of these two drugs in patients with treatment failure on low dose interferon beta. Materials and Methods: The MS patients (McDonald criteria 2010) with the history of unbeneficial treatment on low dose interferon beta participated in this randomized clinical trial ...

In cultured vascular smooth muscle cells, the baseline mRNA and protein levels of an inducible type of nitric oxide synthase were barely detectable. Interferon gamma, tumor necrosis factor-alpha, and interleukin-1 beta each markedly increased mRNA and protein levels of this enzyme in parallel with the production of nitrite, a stable oxidative metabolite of nitric oxide. Actinomycin D abolished ...